BTIG Keeps Their Buy Rating on Insulet (PODD)
In a report released on February 3, Marie Thibault from BTIG maintained a Buy rating on Insulet, with a price target of $380.00. The company’s shares closed yesterday at $251.22.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thibault covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Ceribell, Inc., and Abbott Laboratories. According to TipRanks, Thibault has an average return of -8.8% and a 36.55% success rate on recommended stocks.
In addition to BTIG, Insulet also received a Buy from TipRanks – OpenAI’s OpenAI Medical – Devices in a report issued yesterday. However, on the same day, TipRanks – Anthropic downgraded Insulet (NASDAQ: PODD) to a Hold.
Based on Insulet’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $706.3 million and a net profit of $87.6 million. In comparison, last year the company earned a revenue of $543.9 million and had a net profit of $77.5 million
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2025, Frederick Wayne A.I. , a Director at PODD sold 1,851.00 shares for a total of $542,509.59.
Read More on PODD:
